全球流感疫苗市場：趨勢、預測、競爭分析（~2030 年）

預計2030年，全球流感疫苗市場規模將達112億美元，2024年至2030年複合年成長率為6.8%。該市場的主要促進因素包括對更有效、侵入性更小的流感疫苗的需求不斷增加、人們對流感疫苗益處的認知不斷提高以及政府促進流感疫苗接種的支持措施。全球流感疫苗市場前景廣闊，醫院、零售藥局、政府供應管道都有機會。

• 由於其安全性和有效性，去活化疫苗的需求正在增加，預計在預測期內將出現高速成長。
• 在這個市場中，醫院和零售藥局預計將在預測期內實現最高成長，因為它們是獲得流感疫苗最容易、最容易獲得的地點。
• 由於流感流行率高、醫療保健系統完善以及對疫苗接種的偏好，預計北美在預測期內將經歷最高的成長。

流感疫苗市場新趨勢

流感疫苗市場的新趨勢反映了疫苗技術的創新、擴大可及性和不斷發展的公共衛生策略。這些趨勢正在塑造全球流感預防和治療的未來。

• 四價疫苗和高劑量疫苗的開發：四價疫苗和高劑量疫苗的趨勢引人注目。四價疫苗涵蓋四種流感病毒株並提供更廣泛的保護。高劑量疫苗專為老年人設計，以改善他們的免疫反應。這些進展旨在提高有效性並提供更好的流感保護。
• 專注於疫苗創新和個人化疫苗：疫苗技術的創新，例如針對個人基因特徵量身定做的個人化疫苗，正在獲得動力。此類創新可實現更有效、更有針對性的流感預防，提高疫苗接種率並改善整體公共衛生結果。
• 重視每年接種疫苗：為了因應流感病毒株的季節性波動，每年接種疫苗變得越來越重要。每年的疫苗宣傳活動已廣泛開展，目的是提高疫苗接種覆蓋率並降低流感的年發病率。
• 將疫苗接種計劃擴大到服務欠缺地區：將疫苗接種計劃擴大到服務欠缺地區和農村地區是一個重要趨勢。目前正在努力改善低收入和偏遠地區的疫苗接種機會，以確保更廣泛的覆蓋範圍並縮小流感預防的差距。
• 與數位健康解決方案整合：與電子健康記錄和行動醫療應用程式等數位健康解決方案整合正在改善疫苗追蹤和管理。數位工具可以幫助簡化疫苗接種流程、加強公共衛生溝通並提高疫苗遵從率。

新興市場包括四價和高劑量疫苗的開發、注重疫苗創新、強調每年接種疫苗、擴展到服務不足的地區以及與數位健康解決方案的整合等趨勢正在重塑流感疫苗市場。這些趨勢將加強疫苗的功效、可及性和整體公共衛生策略。

流感疫苗市場近期趨勢

流感疫苗市場的最新趨勢以技術進步、監管更新和公共衛生策略改進為標誌。這些發展正在改變疫苗的有效性和可用性。

• 四價疫苗的推出：四價疫苗的推出是一項重要的發展，因為與三價疫苗相比，它多了一種株。這些疫苗提供更廣泛的保護，正在成為流感預防的標準，提高整體功效並減少季節性流感發病率。
• 高劑量和佐劑疫苗的進展：高劑量和佐劑疫苗是專門為增強老年人的免疫反應而開發的。這些疫苗旨在解決與老齡化相關的免疫力下降問題，提供更好的保護，並降低與流感相關的嚴重併發症的風險。
• 擴大疫苗取得計畫：透過政府補貼和公共衛生計畫擴大疫苗取得的努力正在加大。這些計劃旨在使疫苗更便宜、更容易獲得，特別是對於服務不足的人群和農村地區，並提高疫苗接種率和公共衛生結果。
• 新疫苗配方的出現：正在推出新的疫苗配方，包括具有改進的多系統保護的疫苗配方。這些配方提高了我們應對不斷變化的流感病毒的能力，提高了疫苗功效，並有助於更好地管理季節性流感。
• 疫苗分配的全球合作：政府、製藥公司和衛生組織之間的全球合作改善了疫苗分配。這些夥伴關係透過擴大疫苗對不同族群（包括低收入和中等收入國家）的覆蓋範圍，加強了全球流感預防工作。

四價疫苗的引入、高劑量和佐劑疫苗的進步、擴大准入計劃、新配方的出現以及全球合作等近期趨勢正在對流感疫苗市場產生重大影響。這些進步正在提高疫苗的功效、可及性和整體公共衛生結果。

流感疫苗市場的策略性成長機會

疫苗技術的進步、全球疫苗接種工作的不斷增加以及不斷變化的公共衛生需求推動了流感疫苗市場的策略性成長機會。這些機會代表了市場擴張和改善健康結果的潛力。

• 擴展到新興市場：將流感疫苗接種計劃擴展到新興市場代表著巨大的成長機會。針對疫苗接種覆蓋率低和疾病負擔高的地區可以透過降低流感發病率來推動市場成長並改善全球健康。
• 開發下一代疫苗：投資開發下一代流感疫苗開啟了成長機會，包括具有更廣泛病毒株覆蓋範圍和更高功效的疫苗。這些疫苗可以解決當前的限制並滿足不斷變化的公共衛生需求，從而促進市場創新和擴張。
• 與公共衛生計劃的整合：將流感疫苗整合到現有的公共衛生計劃中，例如常規免疫接種和季節性健康宣傳活動，提供了成長機會。將疫苗納入綜合健康策略可以提高疫苗接種覆蓋率並更好地預防和控制疾病。
• 數位健康和​​疫苗追蹤的進步：利用數位健康解決方案來追蹤和管理疫苗帶來了成長機會。行動應用程式和電子健康記錄等數位工具可以增強疫苗接種流程、提高依從率並簡化公共衛生活動。
• 策略夥伴關係和協作：與政府、非政府組織和私部門的策略夥伴關係和協作可以加強疫苗的分發和取得。這些夥伴關係可以透過提高疫苗供應、降低成本和擴大服務不足人口的覆蓋範圍來促進市場成長。

流感疫苗市場的策略性成長機會包括擴展到新興市場、開拓下一代疫苗、與公共衛生計劃的整合、數位健康的進步以及戰略夥伴關係。這些機會將推動市場擴張、改善疫苗的取得並改善整體公共衛生結果。

流感疫苗市場推廣因素及挑戰

流感疫苗市場受到多種市場促進因素和挑戰的影響，包括技術進步、經濟因素和監管問題。了解這些因素對於駕馭市場和推動成長至關重要。

推動流感疫苗市場的因素包括：

1.疫苗開發的技術進步：疫苗開發的技術進步：疫苗開發的技術進步，例如新配方和改進的遞送方法，將推動市場開拓。這些創新將透過提高疫苗功效和應對大流行性流感來改善整體公共衛生結果。

2. 公眾意識提升和健康宣傳活動：關於流感疫苗接種重要性的公眾意識提升和健康宣傳活動將促進疫苗的接種。教育措施和有針對性的宣傳活動有助於提高疫苗接種覆蓋率並改善季節性流感的預防。

3. 政府資金和補貼：政府資金和補貼支持流感疫苗接種計劃，使疫苗更容易獲得。財政支持將有助於降低疫苗成本並鼓勵更廣泛的接種，特別是在服務不足和高風險族群中。

4. 流感及相關併發症發生率上升：流感及相關併發症的增加增加了對有效疫苗的需求。流感流行和重症病例數的增加凸顯了改善疫苗接種策略的必要性，從而促進了市場成長。

5. 全球衛生夥伴關係和合作：全球衛生夥伴關係和合作將加強疫苗的分發和取得。政府、非政府組織和私人組織之間的合作將改善疫苗的供應並加速全球流感預防工作。

流感疫苗市場面臨的挑戰包括：

1. 疫苗猶豫和錯誤訊息：疫苗猶豫和錯誤訊息是提高疫苗接種率的挑戰。解決公眾的擔憂並提供準確的資訊對於提高疫苗接種率和疫苗接種計劃的成功至關重要。

2.疫苗成本高：疫苗成本上升會限制疫苗接種，特別是在低收入地區。解決負擔能力問題對於提高疫苗供應和擴大覆蓋範圍至關重要。

3. 監管和合規挑戰：複雜的監管和合規挑戰難以克服。確保遵守不同的地區法規增加了疫苗開發和市場准入的複雜性。

流感疫苗市場的主要促進因素包括技術進步、社會意識的提高、政府的財政支持、流感發病率的上升以及全球衛生夥伴關係。主要挑戰包括疫苗接種猶豫、高成本和監管複雜性。解決這些市場促進因素和挑戰對於市場成長和改善公共衛生至關重要。

流感疫苗按市場

本研究按疫苗類型、分銷管道和地區對全球流感疫苗進行了預測。

各國流感疫苗市場前景

流感疫苗市場的最新趨勢集中在疫苗技術進步、監管變化和全球疫苗接種策略。這些發展正在塑造美國、中國、德國、印度和日本等關鍵地區的市場格局。

• 美國：在美國，自從四價疫苗推出以來，流感疫苗市場取得了進展。正在採用具有更高功效的改進配方，並將重點放在年度疫苗宣傳活動上。 FDA 也核准了針對不同年齡層和高風險族群的可改善免疫反應的新疫苗。
• 中國：中國正致力於使用新的國產疫苗配方擴大流感疫苗接種計畫。政府正在加強財政支持和補貼力度，幫助提高疫苗接種率。最近的進展包括新流感疫苗的核准以及提高農村和服務不足地區的疫苗接種覆蓋率以有效緩解季節性流感爆發的努力。
• 德國：德國將更有效的新疫苗納入國家免疫計劃，在流感疫苗市場取得突破。為老年人引入高劑量和輔助疫苗反映了提高疫苗功效的努力。此外，公共衛生宣傳活動正在加強，以鼓勵增加不同族群的疫苗接種覆蓋率。
• 印度：在印度，重點是提高疫苗的可用性和可負擔性。新措施包括推出具有成本效益的流感疫苗和擴大農村地區的疫苗接種計劃。政府和製藥公司之間的夥伴關係旨在改善疫苗分配和疫苗接種覆蓋率，並解決該國季節性流感的沉重負擔。
• 日本：日本透過更新疫苗接種指南和改進疫苗配方開發了流感疫苗市場。值得注意的是，針對多種病毒株的疫苗的推出以及針對成人和兒童的疫苗宣傳活動的擴大。日本也正在投資研究，以開發更有效的疫苗並改善公共衛生對流感的反應。

常問問題

Q.1 流感疫苗的市場規模有多大？

A1. 到2030年，全球流感疫苗市場預計將達到112億美元。

Q.2 流感疫苗市場的成長預測如何？

A2. 2024年至2030年，全球流感疫苗市場預計將以6.8%的複合年成長率成長。

Q.3 影響流感疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要驅動力是對更有效、侵入性更小的流感疫苗的需求不斷成長、人們對流感疫苗益處的認知不斷提高以及政府促進流感疫苗接種的支持措施。

Q4.市場的主要細分市場是：

A4. 流感疫苗市場前景看好，醫院/零售藥局和政府供應管道都有機會。

Q5.市場的主要企業是：

A5. 主要流感疫苗公司如下：

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Q6.未來最大的細分市場是什麼？

A6. 由於去活化疫苗的安全性和有效性，其需求正在增加，我們預計在預測期內將出現高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於流感高發生率、完善的醫療保健系統以及對疫苗接種的偏好，預計北美在預測期內將出現最高的成長。

Q8. 可以客製化報告嗎？

A8. 是的，我們提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球流感疫苗市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球流感疫苗市場趨勢（2018-2023）與預測（2024-2030）
• 全球流感疫苗市場：依疫苗類型
  • 惰性
  • 減毒活
• 全球流感疫苗市場：依分銷管道分類
  • 醫院/藥房
  • 政府供應
  • 其他

第4章市場趨勢與預測分析：按地區分類，2018-2030

• 全球流感疫苗市場：按地區
• 北美流感疫苗市場
• 歐洲流感疫苗市場
• 亞太地區流感疫苗市場
• 其他地區流感疫苗市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按疫苗類型
  • 按分銷管道
  • 按地區
• 全球流感疫苗市場新趨勢
• 戰略分析
  • 新產品開發
  • 全球流感疫苗市場產能擴張
  • 全球流感疫苗市場的合併、收購與合資
  • 認證和許可

第7章主要企業概況

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Influenza Vaccine Trends and Forecast

The future of the global influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

• Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.
• Within this market, hospital & retail pharmacy is expected to witness highest growth over the forecast period as they are the easiest and most accessible locations to acquire a flu vaccine.
• North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Emerging Trends in the Influenza Vaccine Market

Emerging trends in the influenza vaccine market reflect innovations in vaccine technology, expanded access, and evolving public health strategies. These trends are shaping the future of influenza prevention and treatment globally.

• Development of Quadrivalent and High-Dose Vaccines: The trend towards quadrivalent and high-dose vaccines is prominent. Quadrivalent vaccines cover four strains of the influenza virus, offering broader protection. High-dose vaccines are designed for older adults to improve immune response. These developments aim to enhance efficacy and provide better protection against influenza.
• Focus on Vaccine Innovation and Personalized Vaccines: Innovation in vaccine technology, including personalized vaccines tailored to individual genetic profiles, is gaining momentum. These advances promise more effective and targeted influenza prevention, potentially increasing vaccine uptake and improving overall public health outcomes.
• Increased Emphasis on Annual Vaccination: There is a growing emphasis on annual influenza vaccination to address seasonal variations in flu strains. Annual vaccination campaigns are becoming more widespread, aiming to boost vaccine coverage and reduce the incidence of influenza outbreaks each year.
• Expansion of Vaccination Programs to Underserved Areas: Expanding vaccination programs to underserved and rural areas is a key trend. Initiatives to increase vaccine accessibility in low-income and remote regions are being implemented to ensure broader coverage and reduce the disparity in influenza prevention.
• Integration with Digital Health Solutions: Integration of digital health solutions, such as electronic health records and mobile health apps, is improving vaccine tracking and management. Digital tools help streamline vaccination processes, enhance public health communication, and increase vaccine adherence rates.

Emerging trends such as the development of quadrivalent and high-dose vaccines, focus on vaccine innovation, increased emphasis on annual vaccination, expansion to underserved areas, and integration with digital health solutions are reshaping the influenza vaccine market. These trends enhance vaccine effectiveness, accessibility, and overall public health strategies.

Recent Developments in the Influenza Vaccine Market

Recent developments in the influenza vaccine market are marked by technological advancements, regulatory updates, and improved public health strategies. These developments are driving changes in vaccine effectiveness and accessibility.

• Introduction of Quadrivalent Vaccines: The introduction of quadrivalent vaccines, which cover an additional strain compared to trivalent vaccines, represents a significant development. These vaccines offer broader protection and are becoming the standard for influenza prevention, improving overall efficacy and reducing seasonal flu incidence.
• Advancements in High-Dose and Adjuvanted Vaccines: High-dose and adjuvanted vaccines have been developed to enhance immune response, especially in older adults. These vaccines are designed to address age-related declines in immunity, providing better protection and reducing the risk of severe influenza-related complications.
• Expansion of Vaccine Access Programs: Efforts to expand vaccine access through government subsidies and public health programs have increased. These programs aim to make vaccines more affordable and accessible, particularly in underserved populations and rural areas, thereby improving vaccination rates and public health outcomes.
• Emergence of New Vaccine Formulations: New vaccine formulations, including those with improved protection against multiple strains, have been introduced. These formulations enhance the ability to address evolving influenza viruses and improve vaccine effectiveness, contributing to better seasonal flu management.
• Global Collaboration for Vaccine Distribution: Global collaboration among governments, pharmaceutical companies, and health organizations has improved vaccine distribution. These partnerships help ensure that vaccines reach diverse populations, including those in low- and middle-income countries, enhancing global influenza prevention efforts.

Recent developments such as the introduction of quadrivalent vaccines, advancements in high-dose and adjuvanted vaccines, expansion of access programs, emergence of new formulations, and global collaboration are significantly impacting the influenza vaccine market. These advancements enhance vaccine effectiveness, accessibility, and overall public health outcomes.

Strategic Growth Opportunities for Influenza Vaccine Market

Strategic growth opportunities in the influenza vaccine market are driven by advancements in vaccine technology, increased global vaccination efforts, and evolving public health needs. These opportunities present potential for market expansion and improved health outcomes.

• Expansion into Emerging Markets: Expanding influenza vaccination programs into emerging markets offers significant growth opportunities. Targeting regions with low vaccination coverage and high disease burden can drive market growth and improve global health by reducing the incidence of influenza.
• Development of Next-Generation Vaccines: Investing in the development of next-generation influenza vaccines, such as those with broader strain coverage and improved efficacy, presents growth potential. These vaccines can address current limitations and meet evolving public health needs, driving market innovation and expansion.
• Integration with Public Health Programs: Integrating influenza vaccines with existing public health programs, such as routine immunizations and seasonal health campaigns, offers growth opportunities. By incorporating vaccines into comprehensive health strategies, vaccination rates can be increased, leading to better disease prevention and management.
• Advancements in Digital Health and Vaccine Tracking: Leveraging digital health solutions for vaccine tracking and management provides growth opportunities. Digital tools, including mobile apps and electronic health records, can enhance vaccination processes, improve adherence rates, and streamline public health efforts.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with governments, NGOs, and private sector players can enhance vaccine distribution and access. These partnerships can facilitate market growth by improving vaccine availability, reducing costs, and expanding coverage to underserved populations.

Strategic growth opportunities in the influenza vaccine market include expansion into emerging markets, development of next-generation vaccines, integration with public health programs, advancements in digital health, and strategic partnerships. These opportunities drive market expansion, improve vaccine accessibility, and enhance overall public health outcomes.

Influenza Vaccine Market Driver and Challenges

The influenza vaccine market is influenced by a range of drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these factors is crucial for navigating the market and fostering growth.

The factors responsible for driving the influenza vaccine market include:

1. Technological Advancements in Vaccine Development: Technological advancements in vaccine development, such as new formulations and improved delivery methods, drive market growth. These innovations enhance vaccine efficacy and address emerging influenza strains, improving overall public health outcomes.

2. Increased Public Awareness and Health Campaigns: Increased public awareness and health campaigns about the importance of influenza vaccination boost vaccine uptake. Educational initiatives and targeted campaigns contribute to higher vaccination rates and better prevention of seasonal flu.

3. Government Funding and Subsidies: Government funding and subsidies support influenza vaccination programs and make vaccines more accessible. Financial support helps reduce vaccine costs and promotes broader coverage, particularly in underserved and high-risk populations.

4. Rising Incidence of Influenza and Related Complications: The rising incidence of influenza and related complications drives demand for effective vaccines. Increased flu outbreaks and severe cases highlight the need for improved vaccination strategies and contribute to market growth.

5. Global Health Partnerships and Collaborations: Global health partnerships and collaborations enhance vaccine distribution and access. Collaborative efforts between governments, NGOs, and private organizations improve vaccine availability and facilitate global influenza prevention initiatives.

Challenges in the influenza vaccine market are:

1. Vaccine Hesitancy and Misinformation: Vaccine hesitancy and misinformation pose challenges to increasing vaccination rates. Addressing public concerns and providing accurate information are essential for improving vaccine uptake and ensuring the success of vaccination programs.

2. High Vaccine Costs: High vaccine costs can limit access, particularly in low-income regions. Addressing affordability issues is crucial for improving vaccine accessibility and achieving broader coverage.

3. Regulatory and Compliance Challenges: Navigating complex regulatory and compliance requirements can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

Major drivers of the influenza vaccine market include technological advancements, increased public awareness, government funding, rising influenza incidence, and global health partnerships. Key challenges include vaccine hesitancy, high costs, and regulatory complexities. Addressing these drivers and challenges is essential for market growth and improving public health outcomes.

List of Influenza Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies influenza vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the influenza vaccine companies profiled in this report include-

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Influenza Vaccine by Segment

The study includes a forecast for the global influenza vaccine by vaccine type, distribution channel, and region.

Influenza Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

• Inactivated
• Live Attenuated

Influenza Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Influenza Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Influenza Vaccine Market

Recent developments in the influenza vaccine market highlight advancements in vaccine technology, regulatory changes, and global vaccination strategies. These developments are shaping the market landscape in key regions including the United States, China, Germany, India, and Japan.

• United States: In the U.S. the influenza vaccine market has seen advancements with the introduction of quadrivalent vaccines, covering additional strains for broader protection. Enhanced formulations with higher efficacy rates are being adopted, and there is increased emphasis on annual vaccination campaigns. The FDA has also approved new vaccines with improved immune responses, targeting diverse age groups and high-risk populations.
• China: China has focused on expanding its influenza vaccination programs with new domestic vaccine formulations. The government has increased funding and subsidies to promote higher vaccine uptake. Recent developments include the approval of new influenza vaccines and efforts to improve vaccination coverage in rural and underserved areas, aiming to mitigate seasonal flu outbreaks effectively.
• Germany: Germany has made strides in the influenza vaccine market by incorporating newer, more effective vaccines into its national immunization program. The introduction of high-dose and adjuvanted vaccines for older adults reflects an effort to boost vaccine efficacy. Additionally, public health campaigns have been intensified to encourage higher vaccination rates across different demographics.
• India: In India, the focus has been on increasing vaccine accessibility and affordability. New initiatives include the launch of cost-effective influenza vaccines and expansion of vaccination programs in rural areas. Government partnerships with pharmaceutical companies aim to enhance distribution and coverage, addressing the high burden of seasonal influenza in the country.
• Japan: Japan has advanced its influenza vaccine market by updating vaccination guidelines and improving vaccine formulations. The introduction of vaccines with enhanced protection against multiple strains and extended vaccination campaigns for both adults and children are notable. Japan is also investing in research to develop more effective vaccines and improve public health responses to influenza.

Features of the Global Influenza Vaccine Market

Market Size Estimates: Influenza vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Influenza vaccine market size by vaccine type, distribution channel, and region in terms of value ($B).

Regional Analysis: Influenza vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, distribution channels, and regions for the influenza vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the influenza vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the influenza vaccine market size?

Answer: The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030.

Q.2 What is the growth forecast for influenza vaccine market?

Answer: The global influenza vaccine market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the influenza vaccine market?

Answer: The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

Q4. What are the major segments for influenza vaccine market?

Answer: The future of the influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key influenza vaccine market companies?

Answer: Some of the key influenza vaccine companies are as follows:

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Q6. Which influenza vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.

Q7. In influenza vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the influenza vaccine market by vaccine type (inactivated and live attenuated), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Influenza Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Influenza Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Influenza Vaccine Market by Vaccine Type
  • 3.3.1: Inactivated
  • 3.3.2: Live Attenuated
• 3.4: Global Influenza Vaccine Market by Distribution Channel
  • 3.4.1: Hospital & Retail Pharmacies
  • 3.4.2: Government Suppliers
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Influenza Vaccine Market by Region
• 4.2: North American Influenza Vaccine Market
  • 4.2.1: North American Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated 4.2.2: North American Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.3: European Influenza Vaccine Market
  • 4.3.1: European Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.3.2: European Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.4: APAC Influenza Vaccine Market
  • 4.4.1: APAC Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.4.2: APAC Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.5: ROW Influenza Vaccine Market
  • 4.5.1: ROW Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.5.2: ROW Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Influenza Vaccine Market by Vaccine Type
  • 6.1.2: Growth Opportunities for the Global Influenza Vaccine Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Influenza Vaccine Market by Region
• 6.2: Emerging Trends in the Global Influenza Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Influenza Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Influenza Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GSK
• 7.2: AstraZeneca
• 7.3: SINOVAC
• 7.4: Pfizer
• 7.5: Vaxess Technologies
• 7.6: CSL
• 7.7: EMERGENT